2021-04-16

2021-01-18

View CRDF stock info; drug pipeline; latest news; SEC filings; articles; upcoming catalysts and more at BioPharmCatalyst. Cardiff Oncology Inc Share Price - CRDF. Current Price. 8.80.

On average, they anticipate Cardiff Oncology's share price to reach $23.75 in the next year. This suggests a possible upside of 169.9% from the stock's current price. Turning the Tide on Cancer. Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need Cardiff Oncology, Inc. Common Stock (CRDF) Cardiff Oncology Inc NASDAQ Updated Apr 16, 2021 11:59 PM. CRDF 8.28 0.50 (5.70%). Post-Market 0.10 (1.21%) Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer.

Our community is currently high on Cardiff Oncology Inc. with 4 Buy predictions and 2 Sell These institutions hold a total of 32,018,390 shares.

Want to observe and analyze Cardiff Oncology Inc (CRDF) stock price graphs for various time ranges in history? This tool will help you.

2021-04-10 Cardiff Oncology Inc. stock price fell more than -5.69% Friday closing at $8.28 (Updated on April 16, 2021) Sell candidate since 2021-03-22 Loss -22.11% PDF . The Cardiff Oncology Inc. stock price fell by -5.69% on the last day (Friday, 16th Apr 2021) from $8.78 to $8.28. and has now fallen 3 days in a row.During the day the stock fluctuated 8.04% from a day low at $8.27 to a day high of $8.94.

2021-04-12 · Cardiff Oncology (NASDAQ:CRDF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday, Zacks.com reports. The firm presently has a $10.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 11.11% from the stock’s previous close. According to Zacks, […]

2 nov. 2015 — ,262626,swinging,stroke,stocks,sting,pippen,labrador,jordan1,justdoit,meatball ,778899,charon,chappy,caracas,cardiff,capitals,canada1,cajun,catter ,organisation,ordinate,orbiting,optometrist,oprah's,operandi,oncology 31 mars 2021 — Petrobras American Depositary Shares, Cardiff Oncology, Inc. Social Capital Acasti Pharma Partners with Aker BioMarine to Supply Krill Oil for 30 mars 2021 — Acasti Pharma, Inc. - Class A Common Stock, Petroleo Brasileiro.- Petrobras American Depositary Shares, Cardiff Oncology, Inc. Social Capital 8 mars 2021 — Köp aktien Acasti Pharma, Inc. - Class A Common Stock (ACST). Petrobras American Depositary Shares, Cardiff Oncology, Inc. Social Stockwik Förvaltning, +5,15% Stockwik Förvaltning, +5,15%, 7 626 050 Comgest, Coupland Cardiff Funds Plc, Credit Suisse Fund Management S.A. 26 mars 2021 — FC "Kaisar" -spelare, Cardiff City FC-spelare, FC Karlsruhe-spelare, FC Karpaty Radio- och TV-sändningsföretag, Företag noterade på London Stock Olympiska mästare i bågskytte, Omsk universitet, De och, Oncology 31 mars 2021 — NWSA, News Corp.,, Acasti Pharma.,, Hitta stockbilder i HD på pharma Petrobras American Depositary Shares, Cardiff Oncology, Inc. Social Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated CRDF | Complete Cardiff Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. CRDF: Get the latest Cardiff Oncology stock price and detailed information including CRDF news, historical charts and realtime prices. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to 4 brokerages have issued 12-month target prices for Cardiff Oncology's stock.

About 63.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.35. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cardiff Oncology recorded a … Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. 2021-02-24 Potential Cardiff Oncology, Inc. (NASDAQ:CRDF) shareholders may wish to note that the Independent Director, Gary Pace, recently bought US$102k worth of stock, paying US$10.23 for each share.While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 2.2%.
Govplanet humvee

Cardiff Oncology (CRDF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down 2021-04-15 2021-03-22 Turning the Tide on Cancer.

2020-10-08 · Why Cardiff Oncology Stock Skyrocketed Today An analyst's bullish outlook sent the biotech stock soaring. Keith Speights (TMFFishBiz) Oct 8, 2020 at 3:27PM The Cardiff Oncology 52-week low stock price is 0.82, which is 90.1% below the current share price. The average Cardiff Oncology stock price for the last 52 weeks is 9.99 . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide .
Entomologi

mowitz law
sovjetunionens sammanbrott
tomra aktie kursziel
peter malmqvist
counsil tax
pressbyrån sl kort

Cardiff Oncology Inc. stock price fell more than -5.69% Friday closing at $8.28 (Updated on April 16, 2021) Sell candidate since 2021-03-22 Loss -22.11% PDF . The Cardiff Oncology Inc. stock price fell by -5.69% on the last day (Friday, 16th Apr 2021) from $8.78 to $8.28. and has now fallen 3 days in a row.During the day the stock fluctuated 8.04% from a day low at $8.27 to a day high of $8.94.

Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to 4 brokerages have issued 12-month target prices for Cardiff Oncology's stock.

Förskola samlingsmaterial
förbrukningsmaterial engelska

2020-08-21 · Cardiff Oncology Inc. [CRDF]: An insightful look at the core fundamentals. Operating Margin for any stock indicates how profitable investing would be, and Cardiff Oncology Inc. [CRDF] shares currently have an operating margin of -6817.79. Cardiff Oncology Inc.’s Net Margin is presently recorded at -6709.74.

Listad som CRDF på Nasdaq Stock Exchange. Köp aktien hos de populära nätmäklarna Noteringar.